BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mirzaei S, Gholami MH, Hashemi F, Zabolian A, Farahani MV, Hushmandi K, Zarrabi A, Goldman A, Ashrafizadeh M, Orive G. Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects. Drug Discov Today 2021:S1359-6446(21)00428-1. [PMID: 34624510 DOI: 10.1016/j.drudis.2021.09.020] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 22.0] [Reference Citation Analysis]
Number Citing Articles
1 Famta P, Shah S, Jain N, Kumar KC, Bagasariya D, Khatri DK, Raghuvanshi RS, Singh SB, Srivastava S. Tumor-promoting aftermath post-chemotherapy: A focus on breast cancer. Life Sciences 2022;310:121125. [DOI: 10.1016/j.lfs.2022.121125] [Reference Citation Analysis]
2 Luo X, Wang G, Wang Y, Wang M, Tan Z, Luo M, Zhang L, Song Y, Jia Y, Zhou H, Qing C. Gibberellin derivative GA-13315 overcomes multidrug resistance in breast cancer by up-regulating BMP6 expression. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1059365] [Reference Citation Analysis]
3 Bagdasaryan AA, Chubarev VN, Smolyarchuk EA, Drozdov VN, Krasnyuk II, Liu J, Fan R, Tse E, Shikh EV, Sukocheva OA. Pharmacogenetics of Drug Metabolism: The Role of Gene Polymorphism in the Regulation of Doxorubicin Safety and Efficacy. Cancers 2022;14:5436. [DOI: 10.3390/cancers14215436] [Reference Citation Analysis]
4 Wu J, Du X, Zhang D, Cui J, Zhang X, Duan X, Trant JF, Li Y. A nanodiamond chemotherapeutic folate receptor-targeting prodrug with triggerable drug release. International Journal of Pharmaceutics 2022. [DOI: 10.1016/j.ijpharm.2022.122432] [Reference Citation Analysis]
5 Paskeh MDA, Ghadyani F, Hashemi M, Abbaspour A, Zabolian A, Javanshir S, Razzazan M, Mirzaei S, Entezari M, Goharrizi MASB, Salimimoghadam S, Aref AR, Kalbasi A, Rajabi R, Rashidi M, Taheriazam A, Sethi G. Biological function and therapeutic perspective of targeting PI3K/Akt signaling in hepatocellular carcinoma: promises and challenges. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106553] [Reference Citation Analysis]
6 Todosenko N, Yurova K, Khaziakhmatova O, Malashchenko V, Khlusov I, Litvinova L. Heparin and Heparin-Based Drug Delivery Systems: Pleiotropic Molecular Effects at Multiple Drug Resistance of Osteosarcoma and Immune Cells. Pharmaceutics 2022;14:2181. [DOI: 10.3390/pharmaceutics14102181] [Reference Citation Analysis]
7 Behroozaghdam M, Dehghani M, Zabolian A, Kamali D, Javanshir S, Hasani Sadi F, Hashemi M, Tabari T, Rashidi M, Mirzaei S, Zarepour A, Zarrabi A, De Greef D, Bishayee A. Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action. Cell Mol Life Sci 2022;79:539. [PMID: 36194371 DOI: 10.1007/s00018-022-04551-4] [Reference Citation Analysis]
8 Famurewa AC, Mukherjee AG, Wanjari UR, Sukumar A, Murali R, Renu K, Vellingiri B, Dey A, Valsala Gopalakrishnan A. Repurposing FDA-approved drugs against the toxicity of platinum-based anticancer drugs. Life Sci 2022;305:120789. [PMID: 35817170 DOI: 10.1016/j.lfs.2022.120789] [Reference Citation Analysis]
9 Li M, Xu Z, Lu W, Wang L, Zhang Y. Potential Pharmacokinetic Effect of Chicken Xenobiotic Receptor Activator on Sulfadiazine: Involvement of P-glycoprotein Induction. Antibiotics (Basel) 2022;11:1005. [PMID: 35892397 DOI: 10.3390/antibiotics11081005] [Reference Citation Analysis]
10 Ashrafizadeh M, Zarrabi A, Karimi‐maleh H, Taheriazam A, Mirzaei S, Hashemi M, Hushmandi K, Makvandi P, Nazarzadeh Zare E, Sharifi E, Goel A, Wang L, Ren J, Nuri Ertas Y, Kumar AP, Wang Y, Rabiee N, Sethi G, Ma Z. (Nano)platforms in bladder cancer therapy: Challenges and opportunities. Bioengineering & Transla Med. [DOI: 10.1002/btm2.10353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Karthika C, Sureshkumar R, Zehravi M, Akter R, Ali F, Ramproshad S, Mondal B, Tagde P, Ahmed Z, Khan FS, Rahman MH, Cavalu S. Multidrug Resistance of Cancer Cells and the Vital Role of P-Glycoprotein. Life (Basel) 2022;12:897. [PMID: 35743927 DOI: 10.3390/life12060897] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
12 Di Giacomo S, Gullì M, Facchinetti R, Minacori M, Mancinelli R, Percaccio E, Scuderi C, Eufemi M, Di Sotto A. Sorafenib Chemosensitization by Caryophyllane Sesquiterpenes in Liver, Biliary, and Pancreatic Cancer Cells: The Role of STAT3/ABC Transporter Axis. Pharmaceutics 2022;14:1264. [PMID: 35745837 DOI: 10.3390/pharmaceutics14061264] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Kiani M, Bagherzadeh M, Ghadiri AM, Makvandi P, Rabiee N. Multifunctional green synthesized Cu-Al layered double hydroxide (LDH) nanoparticles: anti-cancer and antibacterial activities. Sci Rep 2022;12:9461. [PMID: 35676410 DOI: 10.1038/s41598-022-13431-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Rahimmanesh I, Boshtam M, Kouhpayeh S, Khanahmad H, Dabiri A, Ahangarzadeh S, Esmaeili Y, Bidram E, Vaseghi G, Haghjooy Javanmard S, Shariati L, Zarrabi A, Varma RS. Gene Editing-Based Technologies for Beta-hemoglobinopathies Treatment. Biology 2022;11:862. [DOI: 10.3390/biology11060862] [Reference Citation Analysis]
15 Kast RE, Alfieri A, Assi HI, Burns TC, Elyamany AM, Gonzalez-Cao M, Karpel-Massler G, Marosi C, Salacz ME, Sardi I, Van Vlierberghe P, Zaghloul MS, Halatsch ME. MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen. Cancers (Basel) 2022;14:2563. [PMID: 35626167 DOI: 10.3390/cancers14102563] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Yang Z, Xiao T, Li Z, Zhang J, Chen S. Novel Chemicals Derived from Tadalafil Exhibit PRMT5 Inhibition and Promising Activities against Breast Cancer. Int J Mol Sci 2022;23:4806. [PMID: 35563196 DOI: 10.3390/ijms23094806] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Mahabady MK, Mirzaei S, Saebfar H, Gholami MH, Zabolian A, Hushmandi K, Hashemi F, Tajik F, Hashemi M, Kumar AP, Aref AR, Zarrabi A, Khan H, Hamblin MR, Nuri Ertas Y, Samarghandian S. Noncoding RNAs and their therapeutics in paclitaxel chemotherapy: Mechanisms of initiation, progression, and drug sensitivity. J Cell Physiol 2022;237:2309-44. [PMID: 35437787 DOI: 10.1002/jcp.30751] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
18 Entezari M, Sadrkhanloo M, Rashidi M, Asnaf SE, Taheriazam A, Hashemi M, Ashrafizadeh M, Zarrabi A, Rabiee N, Hushmandi K, Mirzaei S, Sethi G. Non-coding RNAs and macrophage interaction in tumor progression. Crit Rev Oncol Hematol 2022;:103680. [PMID: 35405273 DOI: 10.1016/j.critrevonc.2022.103680] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
19 Paskeh MDA, Entezari M, Clark C, Zabolian A, Ranjbar E, Farahani MV, Saleki H, Sharifzadeh SO, Far FB, Ashrafizadeh M, Samarghandian S, Khan H, Ghavami S, Zarrabi A, Łos MJ. Targeted regulation of autophagy using nanoparticles: New insight into cancer therapy. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2022;1868:166326. [DOI: 10.1016/j.bbadis.2021.166326] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
20 Husain A, Makadia V, Valicherla GR, Riyazuddin M, Gayen JR. Approaches to minimize the effects of P-glycoprotein in drug transport: A review. Drug Dev Res 2022. [PMID: 35103340 DOI: 10.1002/ddr.21918] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
21 Lin Y, Liu J, Chang Y, Yu C, Yi W, Lane H, Lu C. Predicting Anticancer Drug Resistance Mediated by Mutations. Pharmaceuticals 2022;15:136. [DOI: 10.3390/ph15020136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Rashedinia M, Nasrollahi A, Shafaghat M, Momeni S, Iranpak F, Saberzadeh J, Arabsolghar R, Sabahi Z. Syringic acid induces cancer cell death in the presence of Cu (II) ions via pro-oxidant activity. Asian Pac J Trop Biomed 2022;12:270. [DOI: 10.4103/2221-1691.345519] [Reference Citation Analysis]
23 Mirzaei S, Gholami MH, Ang HL, Hashemi F, Zarrabi A, Zabolian A, Hushmandi K, Delfi M, Khan H, Ashrafizadeh M, Sethi G, Kumar AP. Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy. Cells 2021;10:3348. [PMID: 34943856 DOI: 10.3390/cells10123348] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
24 Deldar Abad Paskeh M, Asadi S, Zabolian A, Saleki H, Khoshbakht MA, Sabet S, Naghdi MJ, Hashemi M, Hushmandi K, Ashrafizadeh M, Mirzaei S, Zarrabi A, Sethi G. Targeting Cancer Stem Cells by Dietary Agents: An Important Therapeutic Strategy against Human Malignancies. Int J Mol Sci 2021;22:11669. [PMID: 34769099 DOI: 10.3390/ijms222111669] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]